Modality
Nanobody
MOA
MALT1i
Target
JAK1
Pathway
Ferroptosis
IPF
Development Pipeline
Preclinical
Jan 2021
→ Feb 2028
PreclinicalCurrent
NCT04648133
2,630 pts·IPF
2021-01→2028-02·Completed
2,630 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-197mo agoNDA· IPF
2028-02-251.9y awayInterim· IPF
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Complet…
Catalysts
NDA
2025-08-19 · 7mo ago
IPF
Interim
2028-02-25 · 1.9y away
IPF
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04648133 | Preclinical | IPF | Completed | 2630 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |